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Background: Effective processing of a positive result is a key element of a success-
ful newborn screening (NBS) programme. For the UK, this includes information
about carrier status, as we employ an IRT-DNA protocol. In addition, a second
IRT sample is taken at 3−4 weeks for infants with one mutation recognised or a
very high IRT-1. The aim of this survey is to determine what strategies are being
employed and whether targets are being met.
Methods: The survey was conducted through regional CF centres in the UK. The
CF team was provided with the web address for an on-line questionnaire (piloted
on three sites).
Results: 14/27 centres responded. For infants with two mutations, the screening
result was given at a home visit, preceded by a phone call in 13 centres. The
family Health Visitor (HV) made the visit in 13/14, often accompanied by another
health worker (in 9 by a CF Nurse Specialist). One region had specially trained
screening nurses and another screening link Health Visitors, who gave the result.
Hospital assessment was arranged for the following day. The families always saw
a senior CF Physician. For infants requiring a second blood spot sample, practice
was more diverse. A number of respondents recognised a lack of information for
these families and in some cases, families were misinformed about the need for a
second test.
Conclusions: A number of different strategies have been employed to process
a positive screening result and on the whole targets are being achieved. A lack
of information around the second blood spot test was identiﬁed, which has been
addressed with the production of a clear information sheet for professionals to give
these families.
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CF NBS started in the Warsaw CF Centre in September 2006. Screening procedures
are based on IRT/DNA analysis covering the 16 most common mutations in the
Polish population, followed by gene sequencing allowing the diagnosis of over 500
mutations. Infants with positive CF NBS results are called to the CF Centre for
consultation and 2 sweat tests.
From September 2006 to the end of October 2009 there were 345 028 newborns
screened. CF was conﬁrmed in 76 cases, 71 CF children and 182 carriers are
followed in the Warsaw centre. Among CF diagnosed infants 26 (36%) were
F508del homozygotes; 32 (45%) F508del hetertozygotes; and 10 (14%) non-
F508del heterozygotes. In 3 patients only 1 mutaton was found. The average age
at diagnosis was 44 days, the mean sweat test value − Cl 67.8mmol/l. There were
15 infants (21%) without typical CF symptoms; 6 children (8%) with respiratory
but not gastrointestinal (GI) symptoms; 36 (51%) with gastrointestinal but not
respiratory symptoms (Meconium ileus, steatorrhea, hiperbilirubinemia, failure to
thrive); and 14 (20%) with both types of symptoms. 30% of patients were pancreatic
sufﬁcient. Radiological changes in chest X-rays were observed in 39 cases. At the
time of diagnosis some patients were colonised with Staphylococcus aureus, though
none with Pseudomonas aeruginosa. During the ﬁrst year of life the number of
colonised patients increased and Pseudomonas aeruginosa was conﬁrmed in 10
cases.
Conclusions: We observed some patients with radiological changes without clinical
symptoms. Most of the CF NBS diagnosed infants presented GI symptoms.
Sometimes it was only less weight gain. Most of the patients were pancreatic
insufﬁcient.
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Aims: A two step IRT/DNA programme for CF NBS is widely considered as the
best model, with high sensitivity and speciﬁcity. In our IRT/DNA/IRT programme
a number of collateral events has to be faced: identiﬁcation of carriers, high recall
index with a high number of false positive subjects. Aim of our study is to evaluate a
higher value of b-IRT cut-off for recall in IRT+ve subjects without CFTR mutation
in overcoming some collateral effects, maintaining sensitivity and speciﬁcity.
Methods: Audit of 2004–2007 NBS (384202 newborns) in Lombardy, with a b-IRT
cut off at the 99ºcentile (70 ng/ml). Simulation of the use of two different b-IRT
cut off (at 99.5ºc and 99.8ºc) on the same population. Evaluation of CF incidence,
number of recall and sweat test, number of false negative, sensitivity, speciﬁcity,
VPP.
Results: 2004–2007 NBS programme [b-IRT cut off at 99ºc (70ng/ml)]: CF inci-
dence 1/3961, recall index 1.49%, number sweat test 2023, false negative 7 patients
(3 classic CF), sensitivity 98.8%, speciﬁcity 98.5%, VPP 9.1%. Algorithms with
cut off at 99.5ºc (81ng/ml) and 99.8ºc (104ng/ml): CF incidence 1/4002 and 1/4044
respectively, recall index 0.54% and 0.21%, number sweat test 954 and 715, false
negative 8 pts and 9 pts (3 classic CF), sensitivity 98.6% and 98.4%, speciﬁcity
99.5% and 99.8%, VPP 21.6% and 42%.
Conclusion: A higher b-IRT value for recall could lead to a signiﬁcant lowering
of false positive subjects, with a reduction in referring for sweat test, with the
same capacity in identifying classic CF infants. In order to reach the best NBS
programme for both CF and healthy babies a continuous work of audit and revision
of NBS programmes is needed.
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Background: Since January 2008 a combined IRT/PAP screening for cystic ﬁbrosis
is performed at the eastern part of Saxony, Germany. Objectives and Hypotheses:
As shown by Sarles et al., the use of Pancreatitis associated Protein (PAP) as second
step after IRT elevation could minimize the problems with low IRT speciﬁty, delayed
diagnosis after 2. IRT and unwanted cftr− mutation carrier detection in newborn
screening for cystic ﬁbrosis (CF).
Methods: IRT measurement was done with AutoDELFIA Kit (PerkinElmer, Turku).
To increase sensitivity of PAP measurement, the essential reagents from MucoPAP
Kit (DYNABIO Marseille) were modiﬁed for measurement by DELFIA reaction.
Blood samples from day 2−3, gestational age >32 weeks, were tested for IRT
elevation. For samples exceeding 50 ng/ml PAP measurement was added. All
newborns with an IRT> 50 ng/ml and a PAP> 1.8 ng/ml or IRT> 100 ng/ml and
PAP> 1.0 ng/ml or those with IRT> 150 ng/ml without PAP elevation were sweat
tested.
Results: We tested 35,000 newborn samples. 823 (2.4%) of them had an IRT> 50
and PAP was measured. 64 (0.18%) had elevations in IRT/PAP combination. All of
them got a sweat test. Among the screened population by now 6 CF patients were
diagnosed.
Conclusion: Modiﬁed PAP test fullﬁlls analytical demands for screening puposes
and is comparable to other screening methods. Biochemical CF screening by
IRT/PAP leads to an acceptable recall rate and avoids undesirable carrier identi-
ﬁcation.
